Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial

被引：0
作者：
Kwai Han Yoo
Hyewon Lee
Cheolwon Suh
机构：
[1] Gachon University Gil Medical Center,Division of Hematology, Department of Internal Medicine
[2] National Cancer Center,Center for Hematologic Malignancy
[3] University of Ulsan College of Medicine,Department of Oncology, Asan Medical Center
来源：
International Journal of Hematology | 2018年 / 107卷
关键词：
Lymphoma; Korea; Epidemiology; Clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Lymphomas are a heterogeneous group of disease entities with well-defined clinical, morphological, immunophenotypic, and cytogenetic characteristics. Moreover, regional and racial differences have been reported in their incidence and subtype compositions. Here, we reviewed the epidemiology of lymphomas and summarized the recent achievements in specific subtypes prevalent in Korean population, focusing on clinical studies conducted by the Consortium for Improving Survival of Lymphoma (CISL) of the Korean Society of Hematology Lymphoma Working Party (KSH-LWP).
引用
收藏
页码：395 / 404
页数：9
相关论文
共 366 条
  • [11] Stein H(2018)Nationwide statistical analysis of lymphoid malignancies in Korea Cancer Res Treat. 50 222-38
  • [12] Jaffe ES(2011)Survival of European patients diagnosed with lymphoid neoplasms in 2000–2002: results of the HAEMACARE project Haematologica 96 720-728
  • [13] Swerdlow SH(2016)Cancer treatment and survivorship statistics, 2016 CA Cancer J Clin 66 271-289
  • [14] Campo E(2008)Nasal NK/T-cell lymphoma: epidemiology and pathogenesis Int J Hematol 87 110-117
  • [15] Pileri SA(2016)Extranodal NK/T cell lymphoma, nasal type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in North American and European cases Curr Hematol Malig Rep 11 514-527
  • [16] Harris NL(2014)Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab eras in the United States Anticancer Res 34 5117-5120
  • [17] Stein H(2009)Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma study J Clin Oncol 27 6027-6032
  • [18] Siebert R(2016)A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis Lancet Oncol 17 389-400
  • [19] Park HJ(2011)Efficacy of Blood 117 1834-1839
  • [20] Park EH(2012)-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study Blood 120 2973-2980
12345678910